IceCure Medical (NASDAQ:ICCM) Announces Earnings Results

IceCure Medical (NASDAQ:ICCM) announced its quarterly earnings results on Tuesday. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.01, Yahoo Finance reports. IceCure Medical had a negative return on equity of 101.66% and a negative net margin of 444.30%. The company had revenue of $1.01 million during the quarter, compared to the consensus estimate of $0.90 million. During the same period in the previous year, the business earned ($0.09) EPS.

IceCure Medical Stock Performance

NASDAQ ICCM opened at $0.75 on Thursday. The company has a fifty day moving average of $0.72 and a two-hundred day moving average of $1.03. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.39 and a quick ratio of 2.88. IceCure Medical has a 1 year low of $0.52 and a 1 year high of $1.57. The company has a market capitalization of $34.09 million, a PE ratio of -2.26 and a beta of 0.57.

Analyst Upgrades and Downgrades

Separately, HC Wainwright decreased their target price on IceCure Medical from $3.00 to $2.50 and set a “buy” rating for the company in a research note on Wednesday.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.